Skip to main content
. 2007 Jun 1;24(6):626–634. doi: 10.1111/j.1464-5491.2007.02160.x

Table 1.

Clinical and baseline characteristics of the population studied

Background metformin Background sulphonylurea


Rosiglitazone Sulphonylurea Rosiglitazone Metformin
Patients (n) 259 265 311 284
Age (years) 57 ± 8 57 ± 8 61 ± 8 60 ± 8
Male [n (%)] 141 (54) 139 (52) 152 (49) 149 (52)
Europid [n (%)] 257 (99) 263 (99) 309 (99) 281 (99)
Time from diagnosis (years) 6.1 ± 4.3 7.0 ± 5.6 7.9 ± 5.7 8.1 ± 5.4
Body weight (kg) 93 ± 17 91 ± 15 84 ± 14 83 ± 12
Body mass index (kg/m2) 32.7 ± 5.4 32.3 ± 4.8 30.1 ± 3.8 29.8 ± 3.9
HbA1c (%) 7.9 ± 0.70 7.8 ± 0.66 8.0 ± 0.69 8.0 ± 0.77
Fasting plasma glucose (mmol/l) 9.7 ± 2.38 9.7 ± 2.23 10.2 ± 2.54 10.1 ± 2.24
Homeostasis model assessment %B (%) 30.6 (19.5, 44.2) 30.9 (17.6, 47.3) 24.3 (15.9, 37.9) 22.2 (14.2, 36.8)
Homeostasis model assessment %S (%) 29 (19, 43) 30 (17, 45) 29 (20, 45) 32 (21, 49)
C-reactive protein (mg/l) 3.6 (1.7, 7.2) 3.0 (1.4, 7.1) 2.5 (1.3, 4.6) 2.9 (1.2, 5.2)
Plasminogen activator inhibitor-1 antigen (µg/l) 60 (39, 84) 55 (38, 87) 60 (40, 91) 62 (40, 92)
Fibrinogen (g/l) 3.2 (2.8, 3.7) 3.2 (2.7, 3.6) 3.2 (2.8, 3.7) 3.3 (2.9, 3.8)
Insulin (pmol/l) 61 (41, 89) 57 (39, 97) 57 (36, 80) 53 (34, 71)
Proinsulin (pmol/l) 9.1 (5.8, 16.0) 9.6 (6.3, 15.7) 11.8 (7.7, 19.6) 10.9 (7.0, 17.5)
Proinsulin:insulin ratio (pmol/pmol) 0.16 (0.10, 0.25) 0.16 (0.10, 0.25) 0.23 (0.14, 0.36) 0.23 (0.15, 0.36)
Total cholesterol (mmol/l) 5.4 ± 0.92 5.4 ± 1.02 5.6 ± 1.04 5.6 ± 1.09
Triglycerides (mmol/l) 2.2 ± 1.11 2.1 ± 1.32 2.1 ± 1.88 2.1 ± 1.45
High-density lipoprotein cholesterol (mmol/l) 1.2 ± 0.27 1.2 ± 0.28 1.2 ± 0.31 1.2 ± 0.32
Low-density lipoprotein cholesterol (mmol/l) 3.2 ± 0.79 3.2 ± 0.84 3.5 ± 0.87 3.5 ± 0.96
Non-esterified fatty acids (mmol/l) 0.63 ± 0.22 0.63 ± 0.24 0.66 ± 0.25 0.64 ± 0.24

Number (%), mean ± sd, or median (IQR).